Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care
SAN ANTONIO, July 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") is pleased to report across a series of strategic initiatives for its Entolimod program — including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated 200-fold manufacturing scale-up through its wholly owned subsidiary Velocity Bioworks®, and planned expansion into innovative oncology supportive care.
These developments reflect the Company's evolution from a single product candidate into an integrated biotechnology platform. Taken together, these initiatives have significantly strengthened the Company's ability to pursue multiple avenues of near-, mid- and long-term value creation.
What Happened
During the past weeks, Valion Bio has:
Continued engagement with the Biomedical Advanced Research and Development Authority, or BARDA, the National Institute of Allergy and Infectious Diseases, or NIAID, the Armed Forces Radiobiology Research Institute, or AFRRI, and the U.S. Department of War, or DoW, regarding potential development support and Strategic National Stockpile opportunities for Entolimod.
Continued discussions with Ukraine's Ministry of Health following its previously disclosed Request for Information regarding the potential evaluation of Entolimod for inclusion in Ukraine's national strategic reserves.
Demonstrated an approximately 200-fold manufacturing scale-up of Entolimod through the Company's wholly owned contract development and manufacturing organization, Velocity Bioworks®, at the 50-liter fermentation scale — equivalent to approximately 1.3 million potential human doses, based on the Company's current estimates — while meeting applicable purity and potency specifications.
Advanced preparations to evaluate Entolimod in oncology supportive care, beginning with planned physician-sponsored studies in neutropenia.
Continued development of Entolasta, the Company's next-generation TLR5 agonist, for potential use in oncology supportive care and other immunomodulatory applications.
Why It Matters
These developments support Valion Bio's broader strategy to build an integrated biotechnology platform around a common scientific and manufacturing foundation:
Government preparedness: Entolimod is being advanced as a potential medical countermeasure for Acute Radiation Syndrome, or ARS, under the U.S. Food and Drug Administration's Animal Rule and has received FDA Fast Track and Orphan Drug designations.
Domestic manufacturing: Ownership of Velocity Bioworks provides Valion Bio with greater control over process development, production timing and supply-chain readiness while creating the potential to support future government procurement, internal development programs and third-party CDMO services.
Oncology expansion: The biological activity of the TLR5 platform may support development opportunities beyond biodefense, including oncology supportive care.
Multiple potential value drivers: Valion Bio's strategy is designed to create several potential pathways for advancement through government funding and procurement, clinical development, platform expansion and biomanufacturing.